The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
1. the last we heard BY-HEALTH were intending to make its first submission to the SAMR for Fruitflow® in February 2019.
https://provexis.org/wp-content/uploads/2018/12/PXS_2018-11_Provexis_plc_30-Sep-18_interims_31-Dec-18.pdf
2. plenty of money in the bank.
https://otp.investis.com/clients/uk/provexis_plc/rns/regulatory-story.aspx?cid=1569&newsid=1436931
3. Good question.
Hi all, been quietly watching this one from the sidelines for years now, interested in taking a position however haven't taken the plunge yet, was wondering if somebody would answer a couple of questions if they have time.
Firstly, in terms of the blue cap status, from what I can find when the process was amended a few years back, it was to make it smoother and more efficient. Also from what I can find, to achieve this status shouldn't take anymore than a couple of years, but we're approaching 5 years in this quest? Have I got that right or does someone have a take on why it hasn't happened yet?
Financially, their situation is improving and has been for years although on a slow basis, so another placing looks imminent when there's only 150k left in the bank. From history their doesn't seem to be any rhyme or reason to when these happen, although .7 to .75 looks like a safe bet.
Thirdly, does anyone have any views about the potential here. A 20m cap is nothing in reality in the scheme of things, but given the firm grip that majors have on a market such as this, do people think its plausible that we would be able to jump in and steal marketshare here. The benefits of the product seem to have a huge potential market across the globe, however again is it actually viable for this to emerge as a viable business?
Any thoughts are welcomed!
CB,
You are absolutely 100% correct this time. Fasten your seat belt for the take off probably rockier than SAR.
Could be transformational!!
gixer,
Thanks for the info. Looks like more study for blue hat. Probably something very big is brewing at the background.
Thx Gixer
looks like more grist for the potentially new blood aggregation bluecap category mill?
W$
Cant say its Covid-19 related but here is By-Healths latest study due to start soon.
https://www.chictr.org.cn/showproj.aspx?proj=130349
https://www.chictr.org.cn/showprojen.aspx?proj=130349
I just can't imagine what those with an investment here would say if polled about its benefits.
Wellsite, if not then I suspect it's on the list. We already know they are showing a big interest
https://zhuanlan.zhihu.com/p/387011525
Suspect By-Health have already done a study......
Share sell bid in the 70 s ,a big margin between sell an buys
Not sure how anyone who had felt the full force of Covid could respond to your poll Slam... so that might affect the results.
Have to say I had a few days in bed with it, and felt rough for a week. Also I'll for a few days after first jab, but not the second.
Doesn't seem to prove much.
It would be really interesting to know whether the properties of FF (in all their guises) have had any positive effect on any of us who take the tablets regularly. I guess it wouldn't be a conclusive study but at least it would be quite easy for the Company to do a straw poll of all of us monthly subscribers to identify how many of us have felt the full force of the Covid virus.
CB
to be fair IF has shown himself to be far from reclusive - forgot about the million quid already ?
He "knows" gixer will keep us all on the hook with the stuff that is out there.....yes we all eager for updates but they will come....
Looks like we have another potential bullet on the FF benefits in the guise of anti viral properties......will be interesting to see what Asim's claims are based on
Our million buyer/seller is back
Keep taking the FF
W£
Dippy. The last time I was in a school it was as a pupil!!
We do share one thing in common. That's Sareum. What a ride that's turning out to be. Not a bad investment!
As you say, without Gixer "we would be in total dark" [sic] I assume you mean darkness?
Not much of a reflection on the reclusive CEO is it?
Hi alf,
He/she is retired English teacher and always check everyone's spelling and grammar as got no clue about investment. Top investment banker Stuart Lucas would not invest huge amount of money to own 209m PXS share if it is a dead duck.
https://www.provexis.com/shareholder-information/major-shareholders/
Hi gixer,
Please keep up your excellent work. You are doing a wonderful job for all PXS share holder and are our resident hero. Without your hard work we will be in total dark.
Probably he/she is not aware
Gixer thank you for all your research I really appreciate it (-:
Bid still at 80 no drop
Not looking good
All the be banter about new products Blue cap etc
The market don't agree
Abusive of the best researcher on any chat board.
That sums up the old duffer.
He sold up, bought and sold at the wrong moment, made a loss, blames everyone else.
#trypremiumbonds
Just wondering, did IF misread isolation rules? 10 days not 10 months!!!!!
Paucity of news (what's new about that?)
Gixer, still flogging the dead horse? Are we waiting on blue caps or tin caps!!
The good thing is that AFC are willing to promote "Fruitflow and its relationship with Covid-19". It all helps to get the message out.
It's a minefield though isn't it.
Who's to say there will be any commercial benefit from a medical paper still to be published?
I know you could point to other companies that have done just that, some of whom stretch market abuse rules
I'd like to see more definitive points from the paper when it's public knowledge, and at that point PXS/DSM to explain how that affects prospects for the IP.
Not before.
it would be good if all the links on the news page had a short description/summary of what the linked presentation is all about and why the link has been posted, including context
the title
Fruitflow® and its relationship with COVID-19: AFC LifeScience, SOP Subarashi
Really doesn't inform the reader or encourage anyone to view the link
-- sloppy imo
W$
We've know for a long time now that Fruitflow addresses one of the worst consequences of Covid, sticky blood. The logical conclusion is that daily use would be beneficial in alleviating suffering. It's no surprise that Dr Asim will release medical papers, and publication will further enhance the value of the IP. However, for Provexis to commercialise the IP would involve many hurdles, as have each of the other health claims. Almost taking us back to square one. If some new investors see this as a medium/long term risk, the sp may respond accordingly. Seeing increased revenues from the current IP, especially reaching self sustaining status, would have a much stronger effect IMHO